SEC Company Response from CervoMed Inc. (CRVO) (CIK 0001053691) (CRVO) — May 22, 2019
CervoMed Inc. (CRVO) (CIK 0001053691)
Date: May 22, 2019 · CIK: 0001053691 · Accession: 0001437749-19-010685
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231541
Letter
Re:
dffn20190522_corresp.htm
May 22, 2019
VIA EDGAR
U.S. Securities & Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Diffusion Pharmaceuticals Inc.
Registration Statement on Form S-3 (File No. 333-231541)
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Diffusion Pharmaceuticals Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement be accelerated so that it will become effective as of 5:00 p.m. Eastern Time on May 22, 2019, or as soon thereafter as practicable.
We request that we be notified of such effectiveness by a telephone call to David S. Rosenthal of Dechert LLP at (212) 698-3616, and that such effectiveness also be confirmed in writing. Thank you for your cooperation and attention to this matter.
Sincerely,
Diffusion Pharmaceuticals Inc.
Show Raw Text
CORRESP 1 filename1.htm dffn20190522_corresp.htm May 22, 2019 VIA EDGAR U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Diffusion Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-231541) Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Diffusion Pharmaceuticals Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement be accelerated so that it will become effective as of 5:00 p.m. Eastern Time on May 22, 2019, or as soon thereafter as practicable. We request that we be notified of such effectiveness by a telephone call to David S. Rosenthal of Dechert LLP at (212) 698-3616, and that such effectiveness also be confirmed in writing. Thank you for your cooperation and attention to this matter. Sincerely, Diffusion Pharmaceuticals Inc. By: /s/ David Kalergis Name: David Kalergis Title: Chief Executive Officer cc: William Hornung, Diffusion Pharmaceuticals Inc. David S. Rosenthal, Dechert LLP